A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Status:
Terminated
Trial end date:
2012-02-29
Target enrollment:
Participant gender:
Summary
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the
safety and efficacy of rituximab when administered on a scheduled basis every 6 months over
the course of 1 year with reassessment of response at 12 months. This study is open to
participants previously enrolled in Genentech Study U2971g only.